$SMMT

$17.62▲ +3.6% YTD

3 SEC 13D/G filings tracked · Last updated Sep 13, 2026

Filing History

CP $17.62▲ +3.6%Sep 13, 2026 · ThinkSabio Blog

$SMMT Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-…

News

SMMT ▲ +3.9% - Summit Therapeutics Inc.

CP $18.00▲ +3.9%Sep 9, 2026 · ThinkSabio Blog

$SMMT u/g Buy @ Jefferies pt 25…

News

SMMT ▲ +6.4% - Summit Therapeutics Inc.

CP $15.03▲ +6.4%Sep 2, 2026 · ThinkSabio Blog

$SMMT - Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positiv…